Zenith Epigenetics' ZEN-3694 Receives Orphan Drug Designation from FDA
Alberta and Amsterdam, Netherlands--(Newsfile Corp. - October 27, 2025) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug designation to ZEN-3694 for treatment of NUT carcinoma. NUT carcinoma is a rare, aggressive form of cancer with no currently approved treatments and significant unmet medical need. The Company recently announced Fast Track designation for ZEN-3694 and has stated its...
2025-10-27 8:30 AM EDT
FDA grants Zenith's ZEN-3694 Fast Track Status
Calgary, Alberta--(Newsfile Corp. - July 14, 2025) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") is pleased to announce the designation of ZEN-3694 as a Fast Track product by the U.S. Food and Drug Administration ("FDA"). FDA officials concluded that ZEN-3694, in combination with abemaciclib, meets the criteria for Fast Track designation for the treatment of metastatic or unresectable NUT carcinoma in patients who have received at least one line of prior chemotherapy. The Company is...
2025-07-14 7:15 AM EDT
Zenith Capital Corp. Provides Update on the Company's Upcoming Annual General Meeting
Calgary, Alberta--(Newsfile Corp. - December 16, 2024) - Zenith Capital Corp. ("Zenith" or the "Company") wishes to update shareholders on details regarding the Company's upcoming annual general meeting to be held on January 15, 2025 at 1:00 PM (Calgary Time) (the "Meeting"), including instructions for virtual access to the meeting, as well as potential impacts from the ongoing strike of Canadian Union of Postal Workers on the distribution of the Company's meeting materials (the "Meeting...
2024-12-16 2:05 PM EST
Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
Calgary, Alberta--(Newsfile Corp. - September 24, 2024) - Zenith Capital Corp. ("Zenith" or the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on September 25, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's President & Chief Executive Officer, Donald McCaffrey in real time. Following his presentation, Mr. McCaffrey may open the floor...
2024-09-24 7:15 AM EDT
Zenith Epigenetics Proudly Supports Rare Disease Day
Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases. Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days. This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for...
2024-02-29 9:57 AM EST
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program. The ZEN-3694 program is an advanced epigenetic approach to synergistically advancing the efficacy of cancer treatment of currently marketed drugs. Existing partners and...
2023-10-25 7:51 PM EDT
Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC). NC is a highly aggressive type of squamous cell cancer with very poor prognosis that often forms in the head, neck, or lungs. There are currently no effective treatments for this devastating disease that primarily affects adolescents and young adults with a...
2023-06-01 7:12 AM EDT